Gain-EC: Endometrial cancer
Problem to be solved
Currently, there are limitations in endometrial cancer diagnose, even more accentuated in bleeding post-menopausal women. The main problems detected are: 1) Gold standard is an invasive method and 2) Biopsies are uninformative in a large proportion of women.
Technology
Our asset is a non-invasive test from urine samples designed to identify endometrial cancer and its molecular subtype with the evaluation of somatic mutations and computerized analysis of cytologic images from urine samples. It not only provides a positive/negative result, but also identifies the molecular group (POLE mutated/TP53 mutated) recommended by the ESMO guidelines. It allows early identification of the most appropriate clinical approach and disease monitoring.
Autors
Laura Costas
Technology Readiness Level
TRL4
What are we looking for?
Co-development or investment